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A B S T R A C T
Flexible sigmoidoscopy (FS) screening has been shown to reduce colorectal cancer (CRC) incidence and mor-
tality among screened adults. The aim of this review was to identify patient-related factors associated with the
screening test's use.
We searched PubMed for studies that examined the association between FS screening use and one or more
factors. To determine the eligibility of studies, we ﬁrst reviewed titles, then abstracts, and ﬁnally the full paper.
We started with a narrow search, which we expanded successively (by adding ‘OR’ terms) until the number of
new publications eligible after abstract review was<1% of the total number of publications. We then abstracted
factors from eligible papers and reported the number of times each was found to be positively or negatively
associated with FS screening use.
We identiﬁed 42 papers, most of which reported studies conducted in the United States of America (n= 21,
50%) and the United Kingdom (n= 13, 31%). Across studies, a wide range of factors were examined (n= 123),
almost half of which were found to be associated with FS screening use at least once (n= 60). Sociodemographic
and health and lifestyle factors that were frequently positively associated with FS screening use included: male
gender, higher socioeconomic status and a family history of CRC. Frequently positively associated psychosocial
factors included low perceived barriers and high perceived beneﬁts.
Findings suggest that future research should focus on developing a theoretical framework of cancer screening
behaviour to allow a greater level of consistency and speciﬁcity in measuring key constructs.
1. Background
Colorectal cancer (CRC) is a leading cause of morbidity and mor-
tality in Europe and North America (Ferlay et al., 2015). Several large
randomised controlled trials (RCTs) have shown that a single ﬂexible
sigmoidoscopy (FS) screen between the ages of 55 and 64 can sig-
niﬁcantly reduce the incidence and mortality of the disease among
people who complete the test (Elmunzer et al., 2012). As a result,
several countries have begun implementing FS-based screening pro-
grammes for the early detection and prevention of CRC (Bevan and
Rutter, 2018), with England currently rolling out the test as part of its
national Bowel Cancer Screening Programme (BCSP), and some
healthcare and insurance providers oﬀering it as one of several
screening test options in the United States of America (USA).
As with all screening, the extent to which the public health beneﬁts
of FS screening are realised is highly dependent on uptake (Geurts et al.,
2015). In a recent review of the evidence for FS screening, Littlejohn
and colleagues found that uptake of FS screening was low compared
with other CRC screening tests, such as the guaiac faecal occult blood
test (gFOBt) and faecal immunochemical test (FIT) (Littlejohn et al.,
2012). Indeed, in nine trials that included non-selected samples (i.e.
samples not pre-identiﬁed as ‘willing’ to attend FS), uptake of FS
screening was lower than stool-based screening (i.e. gFOBt or FIT) in
six, the same as FIT in one (gFOBt was not included), and higher than a
combination of FS and gFOBt or FIT in two (Littlejohn et al., 2012).
Researchers exploring low uptake in FS screening have examined
the association between FS screening use and a wide range of factors,
including the perceived barriers and beneﬁts of screening (Tang et al.,
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2001; Power et al., 2008; Sutton et al., 2000; Wardle et al., 2005;
Whitaker et al., 2011), and having a preference for the gender of the
practitioner performing the test (Walsh et al., 2004). To date, reviews of
these studies have combined ﬁndings with those focusing on factors
associated with other CRC screening tests, such as colonoscopy and FIT
(Beydoun and Beydoun, 2008; Wools et al., 2015). For example, in a
recent review by Wools and colleagues, ﬁndings from studies examining
factors associated with colonoscopy screening use and FS screening use
were combined to report factors associated with ‘lower endoscopy’
screening use (Wools et al., 2015). While such reviews are useful in
terms of identifying factors broadly associated with groups of CRC
screening tests, they fail to explore important intrinsic diﬀerences be-
tween tests which might aﬀect peoples' willingness to do each test
diﬀerently. For example, FS only looks at the rectum and sigmoid colon
(Atkin et al., 1993), while colonoscopy examines the whole of the large
bowel, resulting in the need for a more intensive bowel preparation, a
longer time for the procedure, and a higher complication rate (Whitlock
et al., 2008).
The aim of this review, therefore, was to identify factors that have
been frequently associated with FS screening use speciﬁcally. The re-
sults will be used to inform the development of interventions to pro-
mote uptake within the English Bowel Cancer Screening Programme as
part of a research project funded by Yorkshire Cancer Research.
2. Methods
2.1. Search strategy and study selection
We searched PubMed (March 2018) for studies that examined the
association between one or more patient-related factors and FS
screening use. To be eligible, a full text English article had to be
available. Studies were excluded if they examined the association be-
tween patient-related factors and non-screening FS, or any other lower
endoscopic screening test. Trials which examined the impact of one or
more interventions on FS screening use were also excluded, as were
qualitative studies. No other limitations were set in terms of the year of
publication or study design.
An answer to our research question was required within a relatively
short timeframe (six months were allocated to the development of in-
terventions for our Yorkshire Cancer Research study), and so a rapid
review of the available literature was performed. As such, rather than
using the customary search strategy associated with systematic reviews,
which begin as comprehensively as possible, we began with a narrow
search and expanded successively (by adding ‘OR’ terms) until the
number of new publications eligible on abstract review was<1% of
the total (see Table 1). The major assumption with this method was
that, if successive expansions yield diminishing numbers of potentially
eligible publications, and the most recent expansion yields a relatively
small addition to the pool, stopping the expansion at this point is un-
likely to lead to a major loss of information. This search strategy has
previously been described by Duﬀy and colleagues, who found that
92% of papers were identiﬁed prior to reference list searches (i.e. 60 of
65 papers were identiﬁed through the search strategy alone) (Duﬀy
et al., 2017).
The combination and order in which search terms were entered was
based on the total number of new publications obtained at each stage
(i.e. the combination with the highest yield was selected for each stage;
this was to ensure we did not arrive at a ﬁnal search yielding<1% of
new publications potentially eligible for inclusion prematurely). All
papers were assessed by two reviewers (RK and VW). Each reviewer
assigned papers a value of 1 (‘include’) or 0 (‘exclude’). Discrepancies
between reviewer scores were resolved through discussion. Papers
passing title and abstract review underwent full paper review. The re-
ference lists of papers eligible after full paper review were searched for
further potential papers that, in turn, were subject to abstract and, if
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reference lists of reviews detected through the searches (DeBarros and
Steele, 2013; Donovan and Syngal, 1998; St, 2000; Winawer et al.,
1990; Janes et al., 1999; Menees and Fenner, 2007), with two reviewers
assessing the title, abstract and full paper of any potentially eligible
new papers.
2.2. Data collection
Data on the ﬁrst author, year of publication, study setting, pro-
gramme delivery (i.e. organised vs. opportunistic), study design, con-
text (i.e. real life vs. RCT/pilot programme), sample size, outcome,
analysis, gender of participants, factors examined and results were
abstracted from eligible papers. The list of factors accumulated was
then categorised into ‘sociodemographic’, ‘health and lifestyle’ and
‘psychosocial’ factors. For the purposes of this study, sociodemographic
variables were deﬁned as ‘statistical data about the characteristics of a
population’, while health and lifestyle factors were deﬁned as ‘factors
that described the health behaviours, perceived health and previous
medical history of individuals’. Psychosocial variables were deﬁned as
those variables that examined ‘psychological attributes’ (Singh-
Manoux, 2003). To decide whether factors were signiﬁcantly associated
with FS screening use, we used the cut-oﬀ p-value used to deﬁne sta-
tistical signiﬁcance within each individual study.
2.3. Data analysis
Cohen's kappa was used to assess inter-rater agreement for the da-
tabase and reference list searches (Cohen, 1960). Descriptive statistics
were used to report the characteristics of studies and the number of
times factors were examined and found to be positively or negatively




After abstract review, 26 papers were deemed eligible. On full paper
review, 4 were then excluded. From the reference lists of the remaining
papers, and the six identiﬁed review papers, a further 20 were added,
bringing the total number of papers included to 42. Inter-rater agree-
ment for the database and reference list searches was ‘very high’
(Cohen's kappa for the database and reference list searches was 0.87
and 0.92, respectively).
The basic attributes of the included studies are presented in Table 2
(a more detailed overview is presented in Appendix 1). The majority of
papers reported studies performed in the USA (n= 21, 50%) or the UK
(n=13, 31%), examined screening use within opportunistic pro-
grammes (n=22, 52.4%), employed cross-sectional designs (n=30,
71.4%), had sample sizes of> 1000 participants (n=24, 57.1%), and
assessed having attended/ever had a once-only FS screening appoint-
ment (n=29, 65.9%).
3.2. Factors
Across the 42 studies, 123 factors were examined (25 socio-
demographic factors, 50 health and lifestyle factors, and 48 psychoso-
cial factors). The frequencies of factors found to be signiﬁcantly posi-
tively or negatively associated with FS screening use at least once are
reported in Table 3. All consistently non-signiﬁcant factors are reported
in the appendix (see Appendix 2).
3.3. Sociodemographic factors
The most frequently examined sociodemographic factors were:
gender (n=28) (Power et al., 2008; Sutton et al., 2000; Whitaker et al.,
2011; Walsh et al., 2004; Ko et al., 2005; Janz et al., 2003; Walsh et al.,
2002; Lawsin et al., 2007; Taylor et al., 2003; Yip et al., 2006; Blom
et al., 2008; Hol et al., 2009; McGregor et al., 2016; Robb et al., 2010;
Van Jaarsveld et al., 2006; Kang and Bloom, 1993; McCaﬀery et al.,
2002; Bevan et al., 2015; Brotherstone et al., 2007; Juon et al., 2003;
Segnan et al., 2007; Investigators, 2002; Bostick et al., 1993; Lewis and
Jensen, 1995; van Dam et al., 2013; Kremers et al., 2000; Senore et al.,
2010; McCarthy and Moskowitz, 1993), age (n=26) (Power et al.,
2008; Sutton et al., 2000; Wardle et al., 2005; Whitaker et al., 2011;
Walsh et al., 2004; Ko et al., 2005; Janz et al., 2003; Walsh et al., 2002;
Lawsin et al., 2007; Taylor et al., 2003; Yip et al., 2006; Hol et al., 2009;
Van Jaarsveld et al., 2006; Kang and Bloom, 1993; McCaﬀery et al.,
2002; Juon et al., 2003; Segnan et al., 2007; Bostick et al., 1993; Lewis
and Jensen, 1995; van Dam et al., 2013; Kremers et al., 2000; Senore
et al., 2010; McCarthy and Moskowitz, 1993; Richardson et al., 1995;
Brenes and Paskett, 2000; Ruﬃn et al., 2000), education (n=15)
(Sutton et al., 2000; Walsh et al., 2004; Lawsin et al., 2007; Taylor
et al., 2003; Blom et al., 2008; Van Jaarsveld et al., 2006; Juon et al.,
2003; Lewis and Jensen, 1995; van Dam et al., 2013; Kremers et al.,
2000; Senore et al., 2010; McCarthy and Moskowitz, 1993; Richardson
et al., 1995; Brenes and Paskett, 2000; Bostick et al., 1994), marital
status (n=12) (Tang et al., 2001; Power et al., 2008; Wardle et al.,
2005; Lawsin et al., 2007; Taylor et al., 2003; Blom et al., 2008; Van
Jaarsveld et al., 2006; Juon et al., 2003; Lewis and Jensen, 1995; van
Dam et al., 2013; Brenes and Paskett, 2000; Bostick et al., 1994), so-
cioeconomic status (n= 10) (Power et al., 2008; Wardle et al., 2005;
Whitaker et al., 2011; Hol et al., 2009; McGregor et al., 2016; Robb
et al., 2010; McCaﬀery et al., 2002; Bevan et al., 2015; Brotherstone
et al., 2007; van Dam et al., 2013), ethnicity (n=9) (Sutton et al.,
2000; Walsh et al., 2004; Ko et al., 2005; Janz et al., 2003; Walsh et al.,
2002; Lewis and Jensen, 1995; McCarthy and Moskowitz, 1993; Brenes
and Paskett, 2000; Robb et al., 2008), income (n=6) (Tang et al.,
2001; Walsh et al., 2004; Lawsin et al., 2007; Blom et al., 2008; Kang
and Bloom, 1993; Bostick et al., 1994) and employment status (n=5)
(Power et al., 2008; Wardle et al., 2005; van Dam et al., 2013; Senore
et al., 2010; McCarthy and Moskowitz, 1993). Those most frequently
positively associated with FS screening use included: male gender
(n= 12/28; 42.9%) (Sutton et al., 2000; Whitaker et al., 2011; Ko
et al., 2005; Janz et al., 2003; Walsh et al., 2002; Hol et al., 2009;
McGregor et al., 2016; Van Jaarsveld et al., 2006; McCaﬀery et al.,
2002; Segnan et al., 2007; Bostick et al., 1993; McCarthy and
Moskowitz, 1993), higher socioeconomic status (n=9/10; 90%)
(Power et al., 2008; Wardle et al., 2005; Whitaker et al., 2011; Hol
et al., 2009; McGregor et al., 2016; Robb et al., 2010; McCaﬀery et al.,
2002; Bevan et al., 2015; Brotherstone et al., 2007), older age (n=5/
26; 19.2%) (Walsh et al., 2004; Janz et al., 2003; Walsh et al., 2002; Hol
et al., 2009; Ruﬃn et al., 2000), higher education (n=4/15; 26.6%)
(Lawsin et al., 2007; Van Jaarsveld et al., 2006; Kang and Bloom, 1993;
Bostick et al., 1994), being married (n= 4/12; 33.3%) (Wardle et al.,
2005; Blom et al., 2008; Van Jaarsveld et al., 2006; Juon et al., 2003)
and White, Black, or Hispanic ethnicity (n= 5/9; 55.6%) (Walsh et al.,
2004; Ko et al., 2005; Janz et al., 2003; Walsh et al., 2002; Robb et al.,
2008). Other sociodemographic factors examined less frequently, but
found to be positively associated with FS screening use at least once,
included: higher income (n=2/6; 33.3%) (Blom et al., 2008; Bostick
et al., 1994), having a full time job (n=1; 20%) (Wardle et al., 2005)
and being a home owner (n=1; 100%) (Sutton et al., 2000). Negative
associations were reported for two factors: older age (n= 1/26; 3.9%)
(Ko et al., 2005) and male gender (n=1/28; 3.6%) (Blom et al., 2008).
No statistically signiﬁcant positive or negative associations were re-
ported for 11/25 (44%) sociodemographic factors (see Appendix 2),
including social network index (Kang and Bloom, 1993; Bostick et al.,
1994) and access to a car or van (Sutton et al., 2000).
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Table 2
Summary of characteristics of articles included in the review.




USA 21 (50%) (Tang et al., 2001; Walsh et al., 2004; Ko et al., 2005; Janz et al., 2003; Walsh et al., 2002; Lawsin et al., 2007;
Taylor et al., 2003; Yip et al., 2006; Kang and Bloom, 1993; Juon et al., 2003; Bostick et al., 1993; Lewis and
Jensen, 1995; McCarthy and Moskowitz, 1993; Richardson et al., 1995; Brenes and Paskett, 2000; Ruﬃn
et al., 2000; Bostick et al., 1994; Muldoon et al., 1996; Shapiro et al., 2001; Rawl et al., 2004; Thrasher et al.,
2002)
UK 13 (31.0%) (Power et al., 2008; Sutton et al., 2000; Wardle et al., 2005; Whitaker et al., 2011; McGregor et al., 2016;
Robb et al., 2010; Van Jaarsveld et al., 2006; McCaﬀery et al., 2002; Bevan et al., 2015; Brotherstone et al.,
2007; Investigators, 2002; Robb et al., 2008; Vrinten et al., 2015)
The Netherlands 3 (7.0%) (Hol et al., 2009; van Dam et al., 2013; Kremers et al., 2000)
Italy 2 (4.8%) (Segnan et al., 2007; Senore et al., 2010)
Germany 1 (2.4%) (Gölder et al., 2007)
Sweden 1 (2.4%) (Blom et al., 2008)
Norway 1 (2.4%) (Larsen et al., 2006)
Programme delivery
Opportunistic screening 22 (52.4%) (Tang et al., 2001; Walsh et al., 2004; Ko et al., 2005; Janz et al., 2003; Walsh et al., 2002; Lawsin et al., 2007;
Taylor et al., 2003; Yip et al., 2006; Kang and Bloom, 1993; Juon et al., 2003; Bostick et al., 1993; Lewis and
Jensen, 1995; McCarthy and Moskowitz, 1993; Richardson et al., 1995; Brenes and Paskett, 2000; Ruﬃn
et al., 2000; Bostick et al., 1994; Muldoon et al., 1996; Gölder et al., 2007; Shapiro et al., 2001; Rawl et al.,
2004; Thrasher et al., 2002)
Organised screening 20 (47.6%) (Power et al., 2008; Sutton et al., 2000; Wardle et al., 2005; Whitaker et al., 2011; Blom et al., 2008; Hol et al.,
2009; McGregor et al., 2016; Robb et al., 2010; Van Jaarsveld et al., 2006; McCaﬀery et al., 2002; Bevan et al.,
2015; Brotherstone et al., 2007; Segnan et al., 2007; Investigators, 2002; van Dam et al., 2013; Kremers et al.,
2000; Senore et al., 2010; Robb et al., 2008; Larsen et al., 2006; Vrinten et al., 2015)
Study design
Cross-sectional 30 (71.4%) (Tang et al., 2001; Walsh et al., 2004; Ko et al., 2005; Janz et al., 2003; Walsh et al., 2002; Taylor et al., 2003;
Yip et al., 2006; Hol et al., 2009; McGregor et al., 2016; Robb et al., 2010; Van Jaarsveld et al., 2006; Kang
and Bloom, 1993; Bevan et al., 2015; Brotherstone et al., 2007; Juon et al., 2003; Segnan et al., 2007;
Investigators, 2002; Bostick et al., 1993; Lewis and Jensen, 1995; van Dam et al., 2013; Senore et al., 2010;
Richardson et al., 1995; Brenes and Paskett, 2000; Ruﬃn et al., 2000; Bostick et al., 1994; Muldoon et al.,
1996; Shapiro et al., 2001; Rawl et al., 2004; Vrinten et al., 2015; Thrasher et al., 2002)
Prospective 11 (26.2%) (Power et al., 2008; Sutton et al., 2000; Wardle et al., 2005; Whitaker et al., 2011; Lawsin et al., 2007; Blom
et al., 2008; McCaﬀery et al., 2002; Kremers et al., 2000; McCarthy and Moskowitz, 1993; Robb et al., 2008;
Gölder et al., 2007)
Prospective and retrospective 1 (2.4%) (Larsen et al., 2006)
Context
Real world context 22 (52.4%) (Tang et al., 2001; Walsh et al., 2004; Ko et al., 2005; Janz et al., 2003; Walsh et al., 2002; Lawsin et al., 2007;
Taylor et al., 2003; Yip et al., 2006; McGregor et al., 2016; Kang and Bloom, 1993; Juon et al., 2003; Bostick
et al., 1993; Lewis and Jensen, 1995; McCarthy and Moskowitz, 1993; Richardson et al., 1995; Brenes and
Paskett, 2000; Ruﬃn et al., 2000; Bostick et al., 1994; Muldoon et al., 1996; Shapiro et al., 2001; Rawl et al.,
2004; Thrasher et al., 2002)
Pilot programme 6 (14.3%) (Blom et al., 2008; Robb et al., 2010; Bevan et al., 2015; Brotherstone et al., 2007; Kremers et al., 2000;
Gölder et al., 2007)
RCT 14 (33.3%) (Power et al., 2008; Sutton et al., 2000; Wardle et al., 2005; Whitaker et al., 2011; Hol et al., 2009; Van
Jaarsveld et al., 2006; McCaﬀery et al., 2002; Segnan et al., 2007; Investigators, 2002; van Dam et al., 2013;
Senore et al., 2010; Robb et al., 2008; Larsen et al., 2006; Vrinten et al., 2015)
Sample size
<100 1 (2.4%) (Taylor et al., 2003)
100–299 9 (21.4%) (Tang et al., 2001; Lawsin et al., 2007; Yip et al., 2006; Juon et al., 2003; Lewis and Jensen, 1995; Kremers
et al., 2000; McCarthy and Moskowitz, 1993; Brenes and Paskett, 2000; Rawl et al., 2004)
300–999 8 (19.1%) (Whitaker et al., 2011; Walsh et al., 2004; Janz et al., 2003; Kang and Bloom, 1993; Brotherstone et al., 2007;
van Dam et al., 2013; Senore et al., 2010; Gölder et al., 2007)
1000–4999 14 (33.3%) (Power et al., 2008; Sutton et al., 2000; Blom et al., 2008; Hol et al., 2009; Robb et al., 2010; Van Jaarsveld
et al., 2006; Bevan et al., 2015; Bostick et al., 1993; Richardson et al., 1995; Bostick et al., 1994; Robb et al.,
2008; Muldoon et al., 1996; Vrinten et al., 2015; Thrasher et al., 2002)
5000–50,000 7 (16.7%) (Wardle et al., 2005; Walsh et al., 2002; McGregor et al., 2016; McCaﬀery et al., 2002; Segnan et al., 2007;
Ruﬃn et al., 2000; Larsen et al., 2006)




22 (52.4%) (Power et al., 2008; Sutton et al., 2000; Wardle et al., 2005; Whitaker et al., 2011; Blom et al., 2008; Hol et al.,
2009; McGregor et al., 2016; Robb et al., 2010; Van Jaarsveld et al., 2006; McCaﬀery et al., 2002; Bevan et al.,
2015; Brotherstone et al., 2007; Segnan et al., 2007; Investigators, 2002; van Dam et al., 2013; Kremers et al.,
2000; Senore et al., 2010; McCarthy and Moskowitz, 1993; Robb et al., 2008; Gölder et al., 2007; Larsen et al.,
2006; Vrinten et al., 2015)
Ever had FS 6 (14.2%) (Tang et al., 2001; Kang and Bloom, 1993; Juon et al., 2003; Bostick et al., 1993; Lewis and Jensen, 1995;
Bostick et al., 1994)
Up to date with FS 13 (31.0%) (Walsh et al., 2004; Ko et al., 2005; Janz et al., 2003; Walsh et al., 2002; Lawsin et al., 2007; Taylor et al.,
2003; Yip et al., 2006; Richardson et al., 1995; Brenes and Paskett, 2000; Ruﬃn et al., 2000; Muldoon et al.,
1996; Shapiro et al., 2001; Rawl et al., 2004)
Ever had FS and up to date with FS 1 (2.4%) (Thrasher et al., 2002)
(continued on next page)
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3.4. Health and lifestyle factors
The most frequently examined health and lifestyle factors were:
family history of CRC (n=10) (Tang et al., 2001; Sutton et al., 2000;
Wardle et al., 2005; Janz et al., 2003; Walsh et al., 2002; Blom et al.,
2008; Lewis and Jensen, 1995; McCarthy and Moskowitz, 1993; Brenes
and Paskett, 2000; Gölder et al., 2007), perceived health (n= 9)
(Power et al., 2008; Sutton et al., 2000; Wardle et al., 2005; Kang and
Bloom, 1993; Juon et al., 2003; van Dam et al., 2013; Senore et al.,
2010; Richardson et al., 1995; Brenes and Paskett, 2000), insurance
status (n= 7) (Tang et al., 2001; Walsh et al., 2004; Walsh et al., 2002;
Yip et al., 2006; Kang and Bloom, 1993; Juon et al., 2003; Brenes and
Paskett, 2000), smoking status (n= 6) (Sutton et al., 2000; van Dam
et al., 2013; Senore et al., 2010; Bostick et al., 1994; Larsen et al., 2006;
Shapiro et al., 2001), recent bowel symptoms (n= 4) (Power et al.,
2008; Sutton et al., 2000; Wardle et al., 2005; van Dam et al., 2013),
recent mammography (n=4) (Sutton et al., 2000; Walsh et al., 2002;
Brenes and Paskett, 2000; Shapiro et al., 2001), physical activity
(n=4) (Sutton et al., 2000; Senore et al., 2010; Larsen et al., 2006;
Shapiro et al., 2001) and chronic illness (n=3) (Juon et al., 2003;
Bostick et al., 1994; Larsen et al., 2006). Those most frequently posi-
tively associated with FS screening use included: a family history of
CRC (n=5/10; 50%) (Wardle et al., 2005; Walsh et al., 2002; Blom
et al., 2008; McCarthy and Moskowitz, 1993; Gölder et al., 2007), good
perceived health (n= 4/9; 44.4%) (Power et al., 2008; Sutton et al.,
2000; Wardle et al., 2005; Richardson et al., 1995), being a current non-
smoker or smoking fewer than 20 cigarettes a day (n= 3/6; 50%)
(Sutton et al., 2000; Larsen et al., 2006; Shapiro et al., 2001), one or
more recent bowel symptoms (n= 2/4; 50%) (Power et al., 2008;
Wardle et al., 2005), having health insurance (n= 2/7; 28.6%) (Walsh
et al., 2004; Janz et al., 2003) and attending a breast screen within the
last three years (n=2/4; 50%) (Janz et al., 2003; Shapiro et al., 2001).
Other health and lifestyle factors examined less frequently, but found to
be positively associated with FS screening use at least once, included:
visiting a physician within the past year (n= 1/1; 100%) (Bostick et al.,
1994), having a pap smear (n= 1/2; 50%) (Shapiro et al., 2001) or
cholesterol check within the past year (n=1/1; 100%) (Shapiro et al.,
2001), having a usual source of care (n= 1/1; 100%) (van Dam et al.,
2013) and visiting the physician regularly (n= 1/1; 100%) (Lawsin
et al., 2007). Negative associations were reported for two factors:
chronic conditions (n=1/3; 33.3%) (Bostick et al., 1994) and frequent
GP visits within the past three months (n=1/2; 50%) (Wardle et al.,
2005). No statistically signiﬁcant positive or negative associations were
reported for 25 (50%) health and lifestyle factors (see Appendix 2),
including alcohol consumption (Larsen et al., 2006) and being over-
weight (Larsen et al., 2006).
3.5. Psychosocial factors
The most frequently examined psychosocial factors were perceived
barriers (n=7) (Tang et al., 2001; Power et al., 2008; Sutton et al.,
2000; Wardle et al., 2005; Whitaker et al., 2011; Brenes and Paskett,
2000; Rawl et al., 2004), perceived beneﬁts (n= 7) (Power et al., 2008;
Sutton et al., 2000; Wardle et al., 2005; Whitaker et al., 2011; Janz
et al., 2003; Lewis and Jensen, 1995; Senore et al., 2010), perceived risk
(n= 9) (Tang et al., 2001; Power et al., 2008; Sutton et al., 2000;
Wardle et al., 2005; Ko et al., 2005; Lewis and Jensen, 1995; van Dam
et al., 2013; Kremers et al., 2000; Senore et al., 2010; Brenes and
Paskett, 2000), attitudes towards medical tests (n= 3) (Power et al.,
2008; Sutton et al., 2000; Senore et al., 2010), anticipated regret
(n= 2) (Power et al., 2008; van Dam et al., 2013) and receipt of a
physician recommendation to have the test (n= 2) (Lawsin et al., 2007;
Taylor et al., 2003). Those most frequently positively associated with FS
screening use included lower perceived barriers (n= 7/7, 100%) (Tang
et al., 2001; Power et al., 2008; Sutton et al., 2000; Wardle et al., 2005;
Whitaker et al., 2011; Brenes and Paskett, 2000; Rawl et al., 2004),
higher perceived beneﬁts (n= 5/7; 71.4%) (Power et al., 2008; Sutton
et al., 2000; Wardle et al., 2005; Whitaker et al., 2011; Lewis and
Jensen, 1995), higher perceived risk (n=2/9; 22.2%) (Janz et al.,
2003; Kremers et al., 2000), receipt of a recommendation from the
clinician to have the test (n= 2/4; 50%) (Lawsin et al., 2007; Taylor
et al., 2003) and positive attitudes towards medical tests (n= 2/3;
66.7%) (Power et al., 2008; Sutton et al., 2000). Other psychosocial
factors found to be positively associated with FS screening use at least
once, included: lower perceived test pain (n= 1/1; 100%) (Lewis and
Jensen, 1995), higher consideration of future consequences (n= 1/1;
100%) (Whitaker et al., 2011), higher acculturation (n= 1/2; 50%)
(Tang et al., 2001), higher knowledge of FS screening (n=1/1; 100%)
(van Dam et al., 2013), receiving a recommendation to have the test
from a family member (n=1/1; 100%) (Walsh et al., 2004), having
Table 2 (continued)




Univariable analysis 11 (26.2%) (Whitaker et al., 2011; Ko et al., 2005; Yip et al., 2006; Van Jaarsveld et al., 2006; Bevan et al., 2015;
Investigators, 2002; Bostick et al., 1993; McCarthy and Moskowitz, 1993; Ruﬃn et al., 2000; Gölder et al.,
2007; Rawl et al., 2004)
Multivariable regression 29 (69.0%) (Tang et al., 2001; Sutton et al., 2000; Wardle et al., 2005; Walsh et al., 2004; Janz et al., 2003; Walsh et al.,
2002; Lawsin et al., 2007; Taylor et al., 2003; Blom et al., 2008; Hol et al., 2009; McGregor et al., 2016; Robb
et al., 2010; Kang and Bloom, 1993; McCaﬀery et al., 2002; Brotherstone et al., 2007; Juon et al., 2003;
Segnan et al., 2007; Lewis and Jensen, 1995; van Dam et al., 2013; Kremers et al., 2000; Senore et al., 2010;
Richardson et al., 1995; Brenes and Paskett, 2000; Robb et al., 2008; Muldoon et al., 1996; Larsen et al., 2006;
Shapiro et al., 2001; Vrinten et al., 2015; Thrasher et al., 2002)
Discriminant analysis 1 (2.4%) (Power et al., 2008)
Analysis of covariance 1 (2.4%) (Bostick et al., 1994)
Gender of participants
Both 39 (92.9%) (Power et al., 2008; Sutton et al., 2000; Wardle et al., 2005; Whitaker et al., 2011; Walsh et al., 2004; Ko et al.,
2005; Janz et al., 2003; Walsh et al., 2002; Lawsin et al., 2007; Taylor et al., 2003; Yip et al., 2006; Blom
et al., 2008; Hol et al., 2009; McGregor et al., 2016; Robb et al., 2010; Van Jaarsveld et al., 2006; Kang and
Bloom, 1993; McCaﬀery et al., 2002; Bevan et al., 2015; Brotherstone et al., 2007; Juon et al., 2003; Segnan
et al., 2007; Investigators, 2002; Bostick et al., 1993; Lewis and Jensen, 1995; van Dam et al., 2013; Kremers
et al., 2000; Senore et al., 2010; McCarthy and Moskowitz, 1993; Ruﬃn et al., 2000; Bostick et al., 1994; Robb
et al., 2008; Muldoon et al., 1996; Gölder et al., 2007; Larsen et al., 2006; Shapiro et al., 2001; Rawl et al.,
2004; Vrinten et al., 2015; Thrasher et al., 2002)
Females only 3 (7.1%) (Tang et al., 2001; Richardson et al., 1995; Brenes and Paskett, 2000)
Males only 0 (–) –
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previously thought about getting the test done (n=1/1; 100%) (Walsh
et al., 2004) and positive attitudes towards CRC screening tests (n= 1/
1; 100%) (van Dam et al., 2013). Negative associations were reported
for two factors: ﬁnding thoughts about cancer uncomfortable (n=1/1;
100%) (Vrinten et al., 2015) and having a preferred MD gender (n= 1/
1; 100%) (Walsh et al., 2004). No statistically signiﬁcant positive or
negative associations were reported for 27/58 (46.6%) psychosocial
factors (see Appendix 2), including perceived severity (Lewis and
Jensen, 1995; Kremers et al., 2000) and worry about bowel cancer
(Power et al., 2008; Wardle et al., 2005).
3.6. Variance
Three studies reported the amount of variance explained by their
models (Sutton et al., 2000; Whitaker et al., 2011; Janz et al., 2003).
This ranged from 9.9% in a prospective questionnaire study restricted
to individuals who previously indicated that they ‘probably’ or ‘deﬁ-
nitely’ would attend FS screening (Sutton et al., 2000), to 18.3% in a
cross-sectional interview study that used The Health Belief Model as a




This is the ﬁrst review to focus on factors associated with FS
screening use speciﬁcally. As such, it is the ﬁrst to show that a wide
range of factors are frequently associated with the use of this screening
modality. It shows that, consistent with previous reviews examining
factors associated with the use of CRC screening generally, male gender,
higher socioeconomic status, a family history of CRC, good perceived
health status, higher perceived beneﬁts and lower perceived barriers
are all frequently positively associated with FS screening use (Beydoun
and Beydoun, 2008; Wools et al., 2015; Chen et al., 2017; Kiviniemi
et al., 2011). It also shows that, in contrast with previous reviews, being
overweight and having one or more chronic conditions are not fre-
quently positively associated with FS screening use speciﬁcally
(Beydoun and Beydoun, 2008; Wools et al., 2015). Indeed, having one
or more chronic conditions was found to be negatively associated with
FS screening use in one of three studies (no association was observed in
two) (Juon et al., 2003; Bostick et al., 1994; Larsen et al., 2006), while
being overweight was not associated with FS screening use in the one
study that examined it (Larsen et al., 2006). One possible explanation
for this discrepancy is that these factors were only examined in a small
number of studies. Another possible explanation is that qualitative
diﬀerences between screening tests result in some factors acting as a
barrier or facilitator for some tests, but not others. With regard to why
having one or more chronic conditions might be negatively associated
with FS screening use speciﬁcally, and not CRC screening use in gen-
eral, it is possible that chronic conditions, such as diabetes and cardi-
ovascular disease, present practical barriers in terms of getting to the
hospital and performing the bowel preparation, neither of which are
relevant for completing home-based faecal occult blood test kits (by the
same token, chronic conditions might also act as a barrier for colono-
scopy screening; further research is required to test this). Another
possible explanation is that people with certain chronic conditions,
such as cardiovascular disease and high blood pressure, are simply not
clinically eligible for FS, and so are less likely to report having had the
test for this reason. Interviews with people who have chronic diseases
might help explain why these individuals are more likely to complete
one CRC screening test over another. This is only one of several possible
avenues for future research, with a second being to identify the speciﬁc
chronic conditions that inhibit people from attending FS screening, and
a third being to develop interventions for those who have one or more
chronic conditions, but are nonetheless eligible to have the test.
4.2. Contradictions within the literature
There were few contradictions within the literature. Only two fac-
tors, older age and male gender, were found to be both positively and
negatively associated with FS screening use. Contradictions with age
are likely to be due to diﬀerences in the age categories examined. For
example, Ko and colleagues, who published the one study which found
a negative association between older age and FS screening use, ex-
amined FS screening use in adults over the age of 65, and included a
group of 80+ year olds, for whom CRC screening is not recommended
(Ko et al., 2005). With regards to contradictions with gender, these are
more likely to be due to diﬀerences in the way in which individuals are
invited for screening. For example, Blom et al., who published the one
study which found a negative association between male gender and FS
screening use, found that uptake was the same for men and women who
were called by a nurse, but not those who had to call the centre
themselves to make an appointment (Blom et al., 2008).
4.3. Problems with the literature
There are several problems with the literature, the most important
being the lack of/incomplete use of theory. Most studies either did not
use any theory, or only used theory in part. For example, while twelve
studies examined the use of one or more constructs derived from the
Health Belief Model (HBM), only four included all of the model con-
structs and tested the theory as a whole. This issue is exacerbated by a
lack of standardised measures for speciﬁc constructs. For example, in
the seven studies that examined perceived beneﬁts (one of the four
constructs that comprise the HBM), scores were calculated using items
varying in number and content, making it impossible to directly com-
pare the studies.
Another important problem with the literature is that many of the
studies did not explain why they were examining certain factors. For
example, ‘visiting a physician within the previous year’ (Bostick et al.,
1994), ‘having a pap smear within the previous year’ (Shapiro et al.,
2001) and ‘having a cholesterol check within the previous year’
(Shapiro et al., 2001) all eﬀectively examined ‘contact with a health-
care provider within the previous year’. It is possible that these items
could have been combined in the present review, but a lack of ex-
planation/reference to theory meant that it was not possible to assess
whether these factors should be combined without introducing bias.
4.4. Problems with the search strategy
Prior to reference list searches, the database searches detected 22
articles, which equated to 52% of the total. One possible explanation as
to why such a large number of papers was missed by the database
searches, is that search terms were restricted to the title and abstracts of
papers, and most papers examined predictors for more than one CRC
screening test, and consequently did not mention FS screening (or sy-
nonyms of) within the title/abstract speciﬁcally. Had we included more
general terms, such as ‘bowel cancer’ and ‘colorectal cancer’ to our
search strategy, or extended search terms beyond the titles and ab-
stracts, it is likely that those papers detected through the reference list
searches would have been picked up by the database searches.
However, both of these would likely have resulted in a substantial in-
crease in the total number of papers eligible for review, and thereby
prolonged the review process.
4.5. Implications for future research
This review has several implications for future research. It high-
lights a number of demographic subgroups for whom FS screening use
is low, and would therefore beneﬁt from the development of targeted
interventions. These subgroups include women, adults under the age of
65, non-Black and non-Hispanic ethnic minority groups (e.g. Chinese,
R.S. Kerrison et al. Preventive Medicine 120 (2019) 8–18
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Indian and Pakistani), and people who are unmarried or divorced. In
addition, this review highlights a number of modiﬁable psychosocial
factors that could be targeted by interventions to improve FS screening
use. These include the perceived barriers and beneﬁts of screening.
Existing evidence suggests that targeting these factors is likely to be
eﬀective (Wardle et al., 2003; Kerrison et al., 2016; Kerrison et al.,
2017; Kerrison et al., 2018), and that ‘the patient not wanting to do the
preparation’, ‘the healthcare provider not suggesting the test to the
patient’, ‘the patient being worried that the test is uncomfortable or
painful’, and ‘the patient not knowing they should have the test’ are
among the most important barriers to FS screening (although none have
been tested in a multivariate regression, and further research con-
ﬁrming the importance of these barriers is also required) (Jones et al.,
2010).
Another potential area for future research, would be to conduct a
full systematic review separating the predictors of the remaining CRC
screening tests. As identiﬁed in this review, diﬀerent factors appear to
be important for diﬀerent CRC screening tests, and information dis-
tinguishing which factors are important for which tests is currently
lacking. Conducting a systematic review that aims to disentangle which
factors are important for which tests might help inform the develop-
ment of interventions for diﬀerent CRC screening tests, as well as
identify low uptake groups, for whom interventions can be targeted.
4.6. Limitations
This review has several limitations. Most importantly, the search
strategy used was not comprehensive; it was limited to peer-reviewed
articles available on PubMed, and omitted several search terms (e.g.
‘non-compliance’, ‘under-utilisation’, etc.), due to<1% of articles
being identiﬁed by the ﬁnal search (as with the previous searches, the
exact combination and order in which additional search terms would
have been added to the search strategy would have been determined by
the total number of new publications obtained by each of the possible
combinations). As such, it is possible that it did not include several
relevant studies. This is a common problem with rapid reviews, one
which is often accepted in favour of reviewing the literature in a shorter
period of time, usually because the time and resources required for a
comprehensive systematic review are not available (Tricco et al., 2015).
Another important limitation of this review is that it did not include
qualitative research studies (of which the database and reference list
searches identiﬁed seven (Austin et al., 2009; Hall et al., 2016; Holt,
1991; McCaﬀery et al., 2001; Rawl et al., 2000; Ritvo et al., 2013;
Weitzman et al., 2001)). Findings contained within these studies might
help explain the associations identiﬁed within this review. For example,
why it is that men are more likely to use FS screening than women. A
qualitative synthesis of these studies might provide a valuable con-
tribution to the literature.
Finally, this review did not sub-classify studies by design. In addi-
tion, no formal quality assessment was performed, and results were
taken at face value. We have noted the characteristics of studies in the
tables. Researchers should refer to the appendices for further informa-
tion on each of the studies.
4.7. Strengths
This review had a number of strengths. Most importantly, it con-
tained a high number of articles, and had no date restriction imposed.
Furthermore, it focused entirely on FS screening use, and did not mix
ﬁndings with those for other screening tests, or diagnostic FS, meaning
that it was possible to extract factors that were associated with FS
screening use speciﬁcally.
5. Conclusions
The ﬁndings of this review suggest that a number of factors,
including male gender, higher socioeconomic status, a family history of
CRC, good perceived health status, higher perceived beneﬁts and lower
perceived barriers are all frequently positively associated with FS
screening use. In addition, the ﬁndings highlight a number of issues
with the existing literature, including a lack of theory and standardised
measures. Implications for future research include investigating which
chronic conditions act as barriers to FS screening, as well as the de-
velopment of targeted interventions for low uptake groups.
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